메뉴 건너뛰기




Volumn 19, Issue 49, 2000, Pages 5690-5701

Development of inhibitors for protein tyrosine kinases

Author keywords

Cancer therapy; Clinical studies; Drug development; Inhibitors; Preclinical studies; Protein tyrosine kinase

Indexed keywords

3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; 7 HYDROXYSTAUROSPORINE; AG 494; AG 537; AG 982; ALPHA (3,4 DIMETHOXYBENZYLIDENE) 2 PYRIDYLACETONITRILE; BE 23372M; CGP 59326; CLAVILACTONE DERIVATIVE; ERBSTATIN; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; GENISTEIN; IMATINIB; LAVENDUSTIN A; LAVENDUSTIN B; LEFLUNOMIDE; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; PD 0165557; PD 0183805; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUERCETIN; STAUROSPORINE; SU 1498; UNCLASSIFIED DRUG; UNINDEXED DRUG;

EID: 0034693811     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1203926     Document Type: Review
Times cited : (110)

References (125)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.